Kobo Biotech (531541)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Current price ₹4.15 is at the top of the 52-week range (₹1.99-₹4.15), showing speculative interest.
• Reported ROE of 3.79% is positive on a tiny base, though not meaningful with negative ROCE.
• Tiny ₹10 Cr market cap means a small revenue restart could have outsized impact.

Concerns

• Latest quarter shows sales of ₹0 Cr and net profit of -₹1 Cr; there is no operating revenue.
• ROCE of -52.90% indicates severe capital destruction; P/E and book value are not computable.
• Piotroski F-Score of 2/9 signals very weak financial health; profit growth is -8.13%.
• Promoter holding and debt/equity are N/A, so there is no transparency for a retail investor.

AI Analysis

Let me be blunt: Kobo Biotech fails every test Graham would apply. A commodity chemical company with zero quarterly sales, a ₹1 Cr net loss, and ROCE of -52.90% is not a business; it is a shell. At ₹4.15, the market capitalises the company at ₹10 Cr, but with no book value disclosed and no promoter holding, I cannot even check the margin of safety. The Piotroski F-Score of 2/9 screams financial weakness. Reported ROE of 3.79% may look odd, but it is meaningless against negative return on capital and falling profit growth of -8.13%. There is no moat, no pricing power, and no growth. In commodity chemicals, you need scale, low cost, or some unique asset; none is visible from these figures. The 52-week range of ₹1.99 to ₹4.15 shows the stock has doubled, but price action is speculation, not value. With sales at ₹0 Cr, any valuation rests on hope, not earnings. Benjamin Graham said the market is a voting machine in the short run and a weighing machine in the long run. Here, the scales would show a loss-making entity burning capital. I would not call this a turnaround without evidence of a plan, orders, or a restart of operations. A true investor waits for a margin of safety. With book value N/A and negative profits, there is no anchor. At best this is a speculative asset play if there are hidden assets, but I cannot verify. I prefer the certain over the possible. Kobo Biotech is outside my circle of competence and definitely outside Graham's net. I would pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer